[Circulating cardiac antigens in animals with experimental myocardial infarct undergoing malaben pharmacotherapy].
It has been established in chronic experiments on rats that during experimental myocardial infarction, the blood has a complex of heart antigens (up to 250 micrograms/ml). In untreated animals, a high content of heart antigens remains unchanged for a month, slightly diminishing in the second half of the observation period. During malaben treatment, the concentration of heart antigens and duration of their circulation in the blood noticeably decreases which evidences the reduction of the focus of necrosis in the myocardium. It is inferred that determination of the blood content of heart antigens may serve as diagnostic criterion and prognostic test in coronary heart disease subjected to drug therapy.
D010129:4-Aminobenzoic Acid / Q000627:therapeutic use*; D062365:Aminobenzoates / Q000627:therapeutic use*; D000818:Animals; D000941:Antigens / Q000032:analysis*; D004353:Drug Evaluation, Preclinical; D004562:Electrocardiography; D009203:Myocardial Infarction / Q000188:drug therapy / Q000276:immunology*; D009206:Myocardium / Q000276:immunology*; D051381:Rats; D013997:Time Factors; D062366:para-Aminobenzoates
D062365:Aminobenzoates; D000941:Antigens; D062366:para-Aminobenzoates; C002593:disodium 4,4'-9((1,3-dioxo-1,3-propanediyl)diimino)dibenzoate; D010129:4-Aminobenzoic Acid
Tsirkuliruiushchie antigeny serdtsa u zhivotnykh s éksperimental'nym infarktom miokarda v usloviiakh farmakoterapii malabenom.